0V0.F VIMIAN GROUP AB
- Market cap
- EUR 1.97B
- P/E
- 53.3x
- P/B
- 2.63x
- ROE
- 4.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0V0.F undervalued?
Graham number0V0.F trades 149.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VIMIAN GROUP AB fundamental analysis
No fundamental analysis for VIMIAN GROUP AB yet.
VIMIAN GROUP AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VIMIAN GROUP AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applicati…
Full company profileVIMIAN GROUP AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VIMIAN GROUP AB annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 281M | 332M | 375M | 425M | 477M |
| Gross Profit | 194M | 229M | 258M | 293M | 330M |
| Operating Income | 45.2M | 43.4M | 49.5M | 67.6M | 85.3M |
| EBITDA | 39.2M | 70.6M | 88.0M | 105M | 126M |
| Net Income | -6.74M | 9.80M | 18.5M | 31.3M | 36.1M |
| EPS | -0.01 | 0.02 | 0.04 | 0.06 | 0.07 |
| Balance Sheet | |||||
| Total Assets | 924M | 974M | 1.11B | 1.11B | 1.19B |
| Total Liabilities | 442M | 447M | 403M | 401M | 430M |
| Shareholders' Equity | 482M | 526M | 700M | 699M | 748M |
| Cash & Short-term Investments | 42.2M | 37.5M | 64.8M | 55.0M | 55.6M |
| Cash Flow | |||||
| Operating Cash Flow | 25.3M | -28.6M | 58.1M | 106M | 65.9M |
| Capital Expenditure | 10.3M | 14.9M | 14.2M | 15.1M | 20.8M |
| Free Cash Flow | 15.0M | -43.5M | 43.9M | 90.6M | 45.1M |
| Ratios | |||||
| ROE | -1.4% | 1.9% | 2.6% | 4.5% | 4.8% |
| ROA | -0.7% | 1.0% | 1.7% | 2.8% | 3.0% |
| Net Profit Margin | -2.4% | 3.0% | 4.9% | 7.4% | 7.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VIMIAN GROUP AB dividends
VIMIAN GROUP AB has not paid dividends in the last 4 fiscal years.
Who owns VIMIAN GROUP AB
- Insiders 5.44%
- Institutions 85.87%
- Public & others 8.69%
- Shares outstanding 527M
- Free float 189K
VIMIAN GROUP AB company profile
- Company name
- VIMIAN GROUP AB
- Ticker
- 0V0.F
- ISIN
- SE0015961982
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,025
- Fiscal year end
- December
- Address
- Riddargatan 19, Stockholm, Sweden, 11457
- Website
- vimian.com
About VIMIAN GROUP AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
VIMIAN GROUP AB management
10- Mr. Alireza TajbakhshChief Executive Officer · born 1983
- Mr. Carl-Johan Zetterberg BoudrieDeputy CEO, CFO & Interim Head of Specialty Pharma · born 1978
- Ms. Maria Dahllof TullbergHead of IR, Communications & Sustainability · born 1981
- Mr. Carl-Johan EhnGeneral Counsel · born 1974
- Mr. Bart BremerChief People Officer · born 1985
- Mr. Magnus KjellbergChief Executive Officer of Nextmune · born 1973
- Mr. Stefano SantarelliHead of Diagnostics · born 1981
- Mr. Martin BengtsonExecutive Officer
- Michael ThunellHead of Veterinary Services
- Ms. Lotta LundaasHead of MedTech